Blog
Keep up to date with the latest news from Instem.
Introducing Blur™ 2.9: Smarter, Faster Anonymization for Clinical Trial Transparency
As clinical trials transparency needs grow, life sciences teams need more than anonymization—they need a full clinical trial transparency platform.
Driving Pathology Forward: Instem Strengthens Provantis® with Continued Investment and Innovation
These advancements are part of Instem’s broader roadmap focused on efficiency, scalability, and comprehensive study support for your lab team.
The Magical Trinity of TLF Automation in Clinical Trial Analytics: Digital Documents, Metadata, and GenAI
Are we entering a new era for clinical data analysis? An era in which massive time savings, quality improvements, and cost savings can be achieved by automation of the production of tables, listings, and figures...
Instem Moves into New Sustainable, Client-Centric Office at Smartworks 43EQ, Pune, India
Instem is pleased to announce the opening of our new office in Balewadi, Pune, India.
Instem and VICT3R: Pioneering Ethical Innovation in Toxicology Studies
Instem is a contributing partner in the VICT3R Consortium, a collaborative initiative exploring the use of Virtual Control Groups (VCGs) in toxicology studies.
When should we start worrying about SEND v4.0?
Begin considering the systems that collect and report those data and how they may be connecting to your SEND tools. CROs will have far more data and study types that are now modelled in SEND.
7 Major ELN Upgrades with Logbook 6.6
Logbook 6.6 represents our ongoing commitment to delivering tools that evolve with your science. From deep integrations to enhanced compliance and dynamic data handling, this update helps research teams work smarter, faster, and more collaboratively.
Top 8 Features Clinical Analytics Teams Seek in a Clinical Data Analysis System
Read our blog post to learn about the top eight features that biostatistics professionals value most in a clinical data analysis system, and why they matter in today’s landscape of clinical trial analytics.
Significance of Chemical Grouping in E&L Risk Assessment
In Silico Insider: Candice Johnson, PhD